In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Allergan sublicenses neuropathic pain agent to BMS

Executive Summary

Pharmaceutical and device firm Allergan has granted Bristol-Myers Squibb an exclusive worldwide sublicense to develop, manufacture, and sell its Phase II-ready oral neuropathic pain candidate AGN209323 (also called EHT/AGN0001) plus EHT/AGN0002, which is in preclinical studies for pain and neurodegeneration, and other back-up compounds. The deal covers all potential indications except ophthalmology--specifically locally delivered drugs to the eye--to which Allergan retains rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register